دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Addressing Structural Racism and Inequities in Depression Care
Nathalie Moise, MD, MS1; Sidney Hankerson, MD, MBA1,2
doi : 10.1001/jamapsychiatry.2021.1810
JAMA Psychiatry. 2021;78(10):1061-1062
Charting New Phenomenological Paths for Empirical Research on Delusions
Rosa Ritunnano, MD1; Matthew Broome, MD, PhD1; Giovanni Stanghellini, MD2,3
doi : 10.1001/jamapsychiatry.2021.1587
JAMA Psychiatry. 2021;78(10):1063-1064
Intergenerational Effects of Racism
Claudia Lugo-Candelas, PhD1; Lillian Polanco-Roman, PhD2; Cristiane S. Duarte, PhD, MPH1
doi : 10.1001/jamapsychiatry.2021.1852
JAMA Psychiatry. 2021;78(10):1065-1066
Applying Transgenerational Scientific Evidence to the Next Wave of Early Identification Strategies for Psychopathological Risk—Transdiagnostic, Developmental, and Personalized
Andrea Raballo, MD, PhD1,2; Michele Poletti, PsyD3; Antonio Preti, MD4
doi : 10.1001/jamapsychiatry.2021.1901
JAMA Psychiatry. 2021;78(10):1067-1068
Beyond Voluntariness—Ethics and Incentives for Contraception
Anne Drapkin Lyerly, MD, MA1,2
doi : 10.1001/jamapsychiatry.2021.1284
JAMA Psychiatry. 2021;78(10):1069-1070
Efficacy and Cost-Benefit of Onsite Contraceptive Services With and Without Incentives Among Women With Opioid Use Disorder at High Risk for Unintended Pregnancy
Sarah H. Heil, PhD1,2; Heidi S. Melbostad, PhD2; Alexis K. Matusiewicz, PhD1; Catalina N. Rey, PhD1,3; Gary J. Badger, MS4; Donald S. Shepard, PhD5; Stacey C. Sigmon, PhD1,2; Lauren K. MacAfee, MD6; Stephen T. Higgins, PhD1,2
doi : 10.1001/jamapsychiatry.2021.1715
JAMA Psychiatry. 2021;78(10):1071-1078
Rates of in utero opioid exposure continue to increase in the US. Nearly all of these pregnancies are unintended but there has been little intervention research addressing this growing and costly public health problem.
Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death
Felicia Ceban, HBSc1,2; Danica Nogo, HBSc2; Isidro P. Carvalho, HBSc2; Yena Lee, HBSc2; Flora Nasri, MSc2; Jiaqi Xiong, HBSc2; Leanna M. W. Lui, HBSc2; Mehala Subramaniapillai, MSc2,3; Hartej Gill, HBSc2,3; Rene N. Liu, BSc2; Prianca Joseph2; Kayla M. Teopiz2; Bing Cao, PhD2; Rodrigo B. Mansur, MD, PhD2,4; Kangguang Lin, MD, PhD5,6; Joshua D. Rosenblat, MD2,3,4; Roger C. Ho, MD7,8; Roger S. McIntyre, MD2,3,4
doi : 10.1001/jamapsychiatry.2021.1818
JAMA Psychiatry. 2021;78(10):1079-1091
Preexisting noncommunicable diseases (eg, diabetes) increase the risk of COVID-19 infection, hospitalization, and death. Mood disorders are associated with impaired immune function and social determinants that increase the risk of COVID-19. Determining whether preexisting mood disorders represent a risk of COVID-19 would inform public health priorities.
Contingency Management for Patients Receiving Medication for Opioid Use Disorder
Hypatia A. Bolívar, PhD1,2; Elias M. Klemperer, PhD1,2; Sulamunn R. M. Coleman, PhD1,2; Michael DeSarno, MS3; Joan M. Skelly, MS3; Stephen T. Higgins, PhD1,2,4
doi : 10.1001/jamapsychiatry.2021.1969
JAMA Psychiatry. 2021;78(10):1092-1102
Medication treatment for opioid use disorder (MOUD) is efficacious, but comorbid stimulant use and other behavioral health problems often undermine efficacy.
Association of Toxoplasma gondii Seropositivity With Cognitive Function in Healthy People
Lies de Haan, BSc1; Arjen L. Sutterland, MD1; Jasper V. Schotborgh, MD1; Frederike Schirmbeck, PhD1; Lieuwe de Haan, MD, PhD1
doi : 10.1001/jamapsychiatry.2021.1590
JAMA Psychiatry. 2021;78(10):1103-1112
The parasite Toxoplasma gondii has been associated with behavioral alterations and psychiatric disorders. Studies investigating neurocognition in people with T gondii infection have reported varying results. To systematically analyze these findings, a meta-analysis evaluating cognitive function in healthy people with and without T gondii seropositivity is needed.
Reinforcement Learning Disruptions in Individuals With Depression and Sensitivity to Symptom Change Following Cognitive Behavioral Therapy
Vanessa M. Brown, PhD1,2,3; Lusha Zhu, PhD2,4; Alec Solway, PhD2; John M. Wang, PhD1,2; Katherine L. McCurry, PhD1,2; Brooks King-Casas, PhD1,2,5; Pearl H. Chiu, PhD1,2
doi : 10.1001/jamapsychiatry.2021.1844
JAMA Psychiatry. 2021;78(10):1113-1122
Major depressive disorder is prevalent and impairing. Parsing neurocomputational substrates of reinforcement learning in individuals with depression may facilitate a mechanistic understanding of the disorder and suggest new cognitive therapeutic targets.
Association of Brain Reward Response With Body Mass Index and Ventral Striatal-Hypothalamic Circuitry Among Young Women With Eating Disorders
Guido K. W. Frank, MD1; Megan E. Shott, BS1; Joel Stoddard, MD2; Skylar Swindle, BS1; Tamara L. Pryor, PhD3
doi : 10.1001/jamapsychiatry.2021.1580
JAMA Psychiatry. 2021;78(10):1123-1133
Eating disorders are severe psychiatric disorders; however, disease models that cross subtypes and integrate behavior and neurobiologic factors are lacking.
Evaluation of Cognitive Behavioral Therapy vs Mindfulness Meditation in Brain Changes During Reappraisal and Acceptance Among Patients With Social Anxiety Disorder
Philippe R. Goldin, PhD1; Matthew Thurston, MS2; Santiago Allende, MS3; Craig Moodie, PhD4; Matthew L. Dixon, PhD4; Richard G. Heimberg, PhD5; James J. Gross, PhD4
doi : 10.1001/jamapsychiatry.2021.1862
JAMA Psychiatry. 2021;78(10):1134-1142
Cognitive behavioral group therapy (CBGT) and mindfulness-based stress reduction (MBSR) are thought to help patients with social anxiety disorder (SAD) via distinct emotion-regulation mechanisms. However, no study has compared the effects of CBGT and MBSR on brain and negative emotion indicators of cognitive reappraisal and acceptance in patients with SAD.
Associations Between Schizophrenia Polygenic Liability, Symptom Dimensions, and Cognitive Ability in Schizophrenia
Sophie E. Legge, PhD1; Alastair G. Cardno, PhD2; Judith Allardyce, PhD1,3; Charlotte Dennison, BSc1; Leon Hubbard, PhD1; Antonio F. Pardiñas, PhD1; Alexander Richards, PhD1; Elliott Rees, PhD1; Arianna Di Florio, MD, PhD1; Valentina Escott-Price, PhD1; Stanley Zammit, PhD1,4; Peter Holmans, PhD1; Michael J. Owen, PhD1; Michael C. O’Donovan, PhD1; James T. R. Walters, PhD1
doi : 10.1001/jamapsychiatry.2021.1961
JAMA Psychiatry. 2021;78(10):1143-1151
Schizophrenia is a clinically heterogeneous disorder. It is currently unclear how variability in symptom dimensions and cognitive ability is associated with genetic liability for schizophrenia.
Polygenic Risk Scores Derived From Varying Definitions of Depression and Risk of Depression
Brittany L. Mitchell, MSc1,2; Jackson G. Thorp, BSc1,3; Yeda Wu, MD4; Adrian I. Campos, BSc1,3,5; Dale R. Nyholt, PhD2,6; Scott D. Gordon, PhD1; David C. Whiteman, PhD1; Catherine M. Olsen, PhD1; Ian B. Hickie, MD7; Nicholas G. Martin, PhD1; Sarah E. Medland, PhD1; Naomi R. Wray, PhD4,8; Enda M. Byrne, PhD4,9
doi : 10.1001/jamapsychiatry.2021.1988
JAMA Psychiatry. 2021;78(10):1152-1160
Genetic studies with broad definitions of depression may not capture genetic risk specific to major depressive disorder (MDD), raising questions about how depression should be operationalized in future genetic studies.
Race and Ethnicity of Editorial Board Members and Editors as an Indicator of Structural Racism in Psychiatry and Neuroscience Journals
Ruth S. Shim, MD, MPH1; Laura M. Tully, PhD1; Grace Yu2; E. Cristina Monterozza, MD3; Mary Blendermann, BS4
doi : 10.1001/jamapsychiatry.2021.1983
JAMA Psychiatry. 2021;78(10):1161-1163
